Unicycive Therapeutics Stock Today

UNCY Stock  USD 0.41  0.01  2.50%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 23

 
High
 
Low
Low
Unicycive Therapeutics is trading at 0.41 as of the 25th of July 2024; that is 2.50 percent increase since the beginning of the trading day. The stock's open price was 0.4. Unicycive Therapeutics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Unicycive Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of June 2024 and ending today, the 25th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
12th of July 2021
Category
Healthcare
Classification
Health Care
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. The company was incorporated in 2016 and is based in Los Altos, California. Unicycive Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 85.68 M outstanding shares of which 1.47 M shares are at this time shorted by private and institutional investors with about 1.33 trading days to cover. More on Unicycive Therapeutics

Moving together with Unicycive Stock

  0.85CANB Can B CorpPairCorr
  0.62PME Pingtan Marine EnterprisePairCorr

Moving against Unicycive Stock

  0.93WMT Walmart Sell-off TrendPairCorr
  0.91T ATT Inc Buyout TrendPairCorr
  0.9MACAU Moringa Acquisition CorpPairCorr
  0.89AIBBU AIB Acquisition CorpPairCorr
  0.84BAC Bank of America Fiscal Year End 10th of January 2025 PairCorr
  0.76ACACU Acri Capital AcquisitionPairCorr

Unicycive Stock Highlights

Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.04520.0476
Notably Down
Slightly volatile
Gross Profit Margin0.870.5793
Way Up
Slightly volatile
Total Current Liabilities18.4 M17.5 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total656.3 K466 K
Significantly Up
Very volatile
Total Assets7.9 M14.2 M
Way Down
Slightly volatile
Total Current Assets14.1 M13.4 M
Sufficiently Up
Slightly volatile
Debt Levels
Unicycive Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Unicycive Therapeutics' financial leverage. It provides some insight into what part of Unicycive Therapeutics' total assets is financed by creditors.
Liquidity
Unicycive Therapeutics currently holds 811 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest the company is not taking enough advantage from borrowing. Unicycive Therapeutics has a current ratio of 4.34, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Unicycive Therapeutics' use of debt, we should always consider it together with its cash and equity.

Stock Based Compensation

887,920
Unicycive Therapeutics (UNCY) is traded on NASDAQ Exchange in USA. It is located in 4300 El Camino Real, Los Altos, CA, United States, 94022 and employs 14 people. Unicycive Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 34.1 M. Unicycive Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 85.68 M outstanding shares of which 1.47 M shares are at this time shorted by private and institutional investors with about 1.33 trading days to cover. Unicycive Therapeutics currently holds about 10.57 M in cash with (18.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Unicycive Therapeutics Probability Of Bankruptcy
Ownership Allocation
Unicycive Therapeutics shows a total of 85.68 Million outstanding shares. 30% of Unicycive Therapeutics outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Unicycive Ownership Details

Unicycive Stock Institutional Holders

InstituionRecorded OnShares
State Street Corporation2024-03-31
35 K
Virtu Financial Llc2024-03-31
26.1 K
Northern Trust Corp2024-03-31
24 K
Ground Swell Capital, Llc2024-03-31
19.1 K
Captrust Financial Advisors2024-03-31
18.8 K
Tandem Capital Management Corp2024-03-31
15.5 K
Integrated Wealth Concepts Llc2024-03-31
10 K
Tower Research Capital Llc2024-03-31
7.7 K
Ubs Group Ag2024-03-31
4.4 K
Bvf Inc2024-03-31
3.6 M
Ra Capital Management, Llc2024-03-31
3.5 M
View Unicycive Therapeutics Diagnostics

Unicycive Therapeutics Historical Income Statement

At this time, Unicycive Therapeutics' Net Interest Income is fairly stable compared to the past year. Depreciation And Amortization is likely to rise to about 386.4 K in 2024, whereas Interest Expense is likely to drop slightly above 77.9 K in 2024. View More Fundamentals

Unicycive Stock Against Markets

Unicycive Therapeutics Corporate Management

MPA MDChairman, FounderProfile
Pramod GuptaExecutive OperationsProfile
John CPAChief OfficerProfile
Douglas MBAExecutive StrategyProfile

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.